Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $13
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $12 to $13.
Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $12 to $13.